Table 1. Characteristics of metronomic chemotherapy

• frequent (dose-dense) CHT administration without any interruptions
• not using the maximal tolerated dose (MTD) include a biological optimized dose (BOD)
• no application of hematopoetic growth factors
• preference for oral drugs
• low incidence of treatment related side effects
• potential for delayed development of resistance